Compounds > pyrazines
Page last updated: 2024-08-21

pyrazines and Carcinoma, Hepatocellular

pyrazines has been researched along with Carcinoma, Hepatocellular in 57 studies

Research

Studies (57)

TimeframeStudies, this research(%)All Research%
pre-19901 (1.75)18.7374
1990's7 (12.28)18.2507
2000's14 (24.56)29.6817
2010's32 (56.14)24.3611
2020's3 (5.26)2.80

Authors

AuthorsStudies
Ishida, T; Miyauchi, Y; Sawai, M; Takechi, S1
Deng, B; Fang, Z; He, Y; Huang, K; Li, J; Liu, S; Ning, Y; Pan, X; Xu, X; Yang, Z1
Cui, X; Dong, K; Du, Q; Geller, DA; Guo, Y; Yan, Y; Zheng, L1
Chen, D; Liu, M; Qiu, C; Sun, K; Wang, J; Xie, Z1
Fu, X; Guo, H; Li, CL; Lu, J; Nan, KJ; Tian, T; Wang, SH; Yang, YJ; Yao, Y1
Carella, N; Carr, BI; Cavallini, A; D'Alessandro, R; Lippolis, C; Messa, C; Refolo, MG1
Afify, HG; Attia, MS; El-Kemary, M; Elsaady, MM; Hashem, SG; Omer, WE; Youssef, AO1
Chen, KF; Hou, DR; Huang, AC; Shiau, CW; Wang, CY; Yu, HC1
Baiz, D; Chiaretti, S; Consoloni, L; Dapas, B; Farra, R; Fiotti, N; Grassi, G; Pozzato, G; Scaggiante, B; Zanconati, F1
Hong, SY; Kang, S; Min, J; Moon, H; Shin, HH; Yang, HJ1
Amiri, KI; Benson, AB; Berlin, J; Ciombor, KK; Feng, Y; Horton, L; Kauh, JS; Mulcahy, M; Powell, M; Richmond, A; Short, SP; Staley, C; Su, Y1
Cui, A; Hou, J; Hua, H; Jiang, Y; Luo, T; Song, P1
Cai, J; Chen, YJ; Huang, L; Liu, A; Ouyang, Y; Tu, Q; Wang, Y; Xiao, D; Yan, W; Zeng, X; Zeng, Z1
Chu, F; Gong, Y; Lei, H; Li, B; Wang, P; Xu, B; Yan, W; Yao, Q; Zhang, C; Zhang, Y1
Cao, H; Chen, XL; Fu, JP; Shi, J; Tang, ZM; Wan, P1
Auriemma, RS; Colao, A; Cuomo, G; de Angelis, C; De Martino, MC; Hofland, LJ; Izzo, F; Napolitano, M; Negri, M; Pivonello, C; Pivonello, R; Provvisiero, DP; Simeoli, C1
Bi, L; Chen, W; Gao, J; Qian, L; Qiu, S; Yan, X1
Armeanu, S; Baltz, KM; Bitzer, M; Krusch, M; Lauer, UM; Salih, HR; Smirnow, I; Steinle, A; Weiss, TS1
Chen, KF; Cheng, AL; Huang, SY; Lu, YS; Yeh, KH; Yeh, PY1
Kim, SG; Shin, SM1
Baiz, D; Dapas, B; Farra, R; Giansante, C; Grassi, G; Grassi, M; Guarnieri, G; Pozzato, G; Scaggiante, B; Uxa, L; Zennaro, C1
Chen, KF; Chen, PJ; Cheng, AL; Hsieh, HP; Hsu, C; Hsu, CH; Lu, YS; Yeh, PY1
Guillouzo, A; Langouet, S; Morel, F; Piton, A; Rauch, C1
Chen, KF; Chen, PJ; Cheng, AL; Lee, SS; Liu, TH; Yu, HC1
Guo, LY; Li, HL; Liu, M; Liu, Y; Wang, JN; Wang, SS; Wang, XB; Xiang, JZ; Zhang, QF; Zheng, F1
Dhanasekaran, DN; Ha, JH; Jayaraman, M; Kim, SG; Kwak, MK; Lee, CH; Lee, S; Nam, CW; Yang, YM1
Boozari, B; Gürlevik, E; Kloos, A; Knocke, S; Kubicka, S; Kühnel, F; Manns, MP; Mundt, B; Schache, P; Strüver, N; Wirth, TC; Woller, N1
Chen, KF; Chen, PJ; Cheng, AL; Hou, DR; Lin, YC; Liu, CY; Liu, TH; Yu, HC1
Boyer, M; Erlichman, C; Holen, K; Kim, GP; Mahoney, MR; Marshke, R; Mok, TS; Nowak, A; Philip, PA; Picus, J; Pitot, HC; Rubin, J; Szydlo, D; Wright, JJ1
Chen, HJ; Chen, KF; Chen, PJ; Chen, YC; Cheng, AL; Hou, DR; Liu, CY; Yu, HC1
Eckhardt, SG; Kulikowski, GN; Morelli, MP; Pitts, TM; Serkova, NJ; Spratlin, JL; Tentler, JJ1
Buck, E; Desai, V; Epstein, DM; Miglarese, M; Wang, J; Zhao, H1
Ding, ZB; Fan, J; Gu, CY; Hui, B; Liu, WR; Peng, YF; Shi, GM; Shi, YH; Yang, H; Zhou, J1
Gao, D; Guo, K; Jiang, K; Jin, G; Kang, X; Li, Y; Liu, Y; Shu, H; Sun, C; Sun, H; Sun, L; Wang, C; Wu, W1
Banerjee, A; Gartel, AL; Halasi, M; Kabirov, K; Landolfi, J; Lyubimov, AV; Wang, M1
Chang, TC; Chen, SC; Jan, YJ; Ko, BS; Liang, SM; Liou, JY; Liu, TA; Wang, J; Wu, YM1
Bantel, H; Kontermann, R; Krech, T; Länger, F; Lehner, F; Manns, MP; Nüssler, A; Pfizenmaier, K; Schulze-Osthoff, K; Siegemund, M; Vondran, F; Wahl, K1
Fujisawa, K; Hirose, Y; Matsumoto, T; Murata, Y; Saeki, I; Sakaida, I; Takami, T; Terai, S; Yamamoto, N; Yamasaki, T1
Ishida, T; Takechi, S; Yamaguchi, T1
Chen, KF; Cheng, AL; Hou, DR; Lin, CS; Liu, CY; Shiau, CW; Yu, HC1
Egner, PA; Gange, SJ; Groopman, JD; Jacobson, LP; Kensler, TW; Kuang, SY; Muñoz, A; Qian, GS; Wang, JB; Zhang, BC; Zhu, YR1
Gong, JP; Li, XH; Liu, CA; Mei, Y; Ren, MJ; Shi, YJ; Zuo, GQ1
Chu, H; Kensler, TW; Muñoz, A1
Ganten, TM; Haas, TL; Herzer, K; Koschny, R; Li-Weber, M; Sykora, J; Walczak, H1
Glintborg, B; Kensler, TW; Poulsen, HE; Weimann, A1
Carlisi, D; D'Anneo, A; Di Fazio, P; Emanuele, S; Lauricella, M; Tesoriere, G; Vassallo, B; Vento, R1
Calvaruso, G; Giuliano, M; Pellerito, O; Portanova, P; Tesoriere, G; Vento, R1
Kensler, TW; Yates, MS1
Corral, J; de Arriba, F; Ferrer, F; González, M; Hernández-Espinosa, D; Martínez, C; Miñano, A; Mota, RA; Ordoñez, A; Pérez-Ceballos, E; Vicente, V1
Sato, N; Uehara, M1
Buiatti, E1
Chen, B; Davidson, NE; Egner, PA; Enger, C; Fang, X; Gordon, GB; Gorman, MB; Groopman, JD; Helzlsouer, KJ; Jacobson, LP; Kensler, TW; Kuang, SY; Li, YF; Muñoz, A; Prochaska, HJ; Qian, GS; Wang, JB; Wu, Y; Yu, LY; Zarba, A; Zhang, BC; Zhang, QN; Zhu, YR1
Chen, B; Davidson, NE; Egner, PA; Enger, C; Fang, X; Gordon, GB; Gorman, MB; He, X; Helzlsouer, KJ; Jacobson, LP; Kensler, TW; Kuang, SY; Li, YF; Muñoz, A; Otieno, M; Prochaska, HJ; Qian, GS; Wang, JB; Wang, JS; Wu, Y; Yu, LY; Zarba, A; Zhang, BC; Zhang, QN; Zhu, YR1
Chen, B; Davidson, NE; De Flora, S; Egner, PA; Enger, CL; Fang, X; Gordon, GB; Gorman, MB; Groopman, JD; He, X; Jacobson, LP; Kensler, TW; Kuang, SY; Li, YF; Muñoz, A; Prochaska, HJ; Qian, GS; Wang, JB; Wang, JS; Wu, Y; Yu, LY; Zarba, A; Zhang, BC; Zhang, QN; Zhu, YR1
Kato, A; Kubo, K; Matsuzaki, Y; Okita, K; Terai, S1
Groopman, JD; Jackson, PE1
Epstein, SS; Mantel, N1

Reviews

5 review(s) available for pyrazines and Carcinoma, Hepatocellular

ArticleYear
Strategies for chemoprevention of liver cancer.
    European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2002, Volume: 11 Suppl 2

    Topics: Anticarcinogenic Agents; Carcinoma, Hepatocellular; Chemoprevention; Chlorophyllides; Clinical Trials as Topic; Female; Forecasting; Humans; Liver Neoplasms; Male; Primary Prevention; Prognosis; Pyrazines; Risk Assessment; Thiones; Thiophenes

2002
Keap1 eye on the target: chemoprevention of liver cancer.
    Acta pharmacologica Sinica, 2007, Volume: 28, Issue:9

    Topics: Aflatoxins; Animals; Anticarcinogenic Agents; Antioxidants; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Intracellular Signaling Peptides and Proteins; Isothiocyanates; Kelch-Like ECH-Associated Protein 1; Liver Neoplasms; NF-E2-Related Factor 2; Phenols; Pyrazines; Signal Transduction; Sulfoxides; Thiocyanates; Thiones; Thiophenes; Triterpenes

2007
Chemoprevention of primary liver cancer.
    IARC scientific publications, 1996, Issue:136

    Topics: Anticarcinogenic Agents; Cancer Vaccines; Carcinoma, Hepatocellular; Chemoprevention; Humans; Liver Neoplasms; Nutritional Physiological Phenomena; Pyrazines; Thiones; Thiophenes

1996
Oltipraz chemoprevention trial in Qidong, Jiangsu Province, People's Republic of China.
    Journal of cellular biochemistry. Supplement, 1997, Volume: 28-29

    Topics: Animals; Anticarcinogenic Agents; Carcinoma, Hepatocellular; China; Disease Models, Animal; Double-Blind Method; Humans; Liver Neoplasms; Placebos; Pyrazines; Rats; Thiones; Thiophenes; Treatment Outcome

1997
Aflatoxin and liver cancer.
    Bailliere's best practice & research. Clinical gastroenterology, 1999, Volume: 13, Issue:4

    Topics: Aflatoxins; Animals; Anticarcinogenic Agents; Carcinoma, Hepatocellular; China; Environmental Exposure; Genes, p53; Humans; Incidence; Liver Neoplasms; Mutation; Pyrazines; Thiones; Thiophenes

1999

Trials

8 trial(s) available for pyrazines and Carcinoma, Hepatocellular

ArticleYear
Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group.
    Investigational new drugs, 2014, Volume: 32, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Chemokine CCL5; Cytokines; Disease-Free Survival; Doxorubicin; Female; Humans; Liver Neoplasms; Male; Middle Aged; Pyrazines; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult

2014
An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma.
    Investigational new drugs, 2012, Volume: 30, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Asia; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; North America; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Time Factors; Treatment Outcome; Young Adult

2012
Assessing the effect of interventions in the context of mixture distributions with detection limits.
    Statistics in medicine, 2005, Jul-15, Volume: 24, Issue:13

    Topics: Anticarcinogenic Agents; Biomarkers, Tumor; Carcinogens; Carcinoma, Hepatocellular; China; Double-Blind Method; Humans; Likelihood Functions; Liver Neoplasms; Models, Statistical; Placebos; Pyrazines; Sensitivity and Specificity; Thiones; Thiophenes

2005
Oltipraz chemoprevention trial in Qidong, People's Republic of China: unaltered oxidative biomarkers.
    Free radical biology & medicine, 2006, Sep-15, Volume: 41, Issue:6

    Topics: Anticarcinogenic Agents; Biomarkers; Carcinoma, Hepatocellular; China; DNA; Guanine; Humans; Liver Neoplasms; Oxidation-Reduction; Oxidative Stress; Placebos; Pyrazines; Thiones; Thiophenes

2006
Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin.
    Laboratory investigation; a journal of technical methods and pathology, 2008, Volume: 88, Issue:3

    Topics: Alleles; alpha 1-Antitrypsin; Animals; Antineoplastic Agents; Antithrombins; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Case-Control Studies; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Endoplasmic Reticulum; Factor Xa Inhibitors; Fibrinogen; Humans; Immunohistochemistry; Injections, Intravenous; Leukocyte Elastase; Liver; Liver Neoplasms; Male; Mice; Molecular Chaperones; Multiple Myeloma; Proteasome Inhibitors; Proteins; Pyrazines; Serpins; Ubiquitin

2008
Oltipraz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomes.
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 1997, Volume: 6, Issue:4

    Topics: Adult; Aflatoxins; Aged; Anticarcinogenic Agents; Carcinoma, Hepatocellular; China; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Hepatitis B; Humans; Liver Neoplasms; Male; Middle Aged; Pyrazines; Thiones; Thiophenes

1997
Oltipraz chemoprevention trial in Qidong, People's Republic of China: modulation of serum aflatoxin albumin adduct biomarkers.
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 1998, Volume: 7, Issue:2

    Topics: Adult; Aflatoxins; Aged; Albumins; Anticarcinogenic Agents; Biomarkers; Carcinoma, Hepatocellular; China; Dose-Response Relationship, Drug; Genotype; Glutathione Transferase; Humans; Liver Neoplasms; Middle Aged; Pyrazines; Radioimmunoassay; Risk Assessment; Thiones; Thiophenes

1998
Oltipraz chemoprevention trial in Qidong, Jiangsu Province, People's Republic of China.
    Journal of cellular biochemistry. Supplement, 1997, Volume: 28-29

    Topics: Animals; Anticarcinogenic Agents; Carcinoma, Hepatocellular; China; Disease Models, Animal; Double-Blind Method; Humans; Liver Neoplasms; Placebos; Pyrazines; Rats; Thiones; Thiophenes; Treatment Outcome

1997

Other Studies

45 other study(ies) available for pyrazines and Carcinoma, Hepatocellular

ArticleYear
Dihydropyrazine suppresses TLR4-dependent inflammatory responses by blocking MAPK signaling in human hepatoma HepG2 cells.
    The Journal of toxicological sciences, 2022, Volume: 47, Issue:9

    Topics: Carcinoma, Hepatocellular; Extracellular Signal-Regulated MAP Kinases; Hep G2 Cells; Humans; Lipopolysaccharides; Liver Neoplasms; NF-kappa B; Pyrazines; Signal Transduction; Toll-Like Receptor 4

2022
Piezo1 impairs hepatocellular tumor growth via deregulation of the MAPK-mediated YAP signaling pathway.
    Cell calcium, 2021, Volume: 95

    Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle Proteins; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Ion Channels; Liver Neoplasms; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Pyrazines; Signal Transduction; Thiadiazoles; Transcription Factors; Tumor Burden

2021
Interferon regulatory factor 1 (IRF-1) downregulates Checkpoint kinase 1 (CHK1) through miR-195 to upregulate apoptosis and PD-L1 expression in Hepatocellular carcinoma (HCC) cells.
    British journal of cancer, 2021, Volume: 125, Issue:1

    Topics: Animals; Apoptosis; B7-H1 Antigen; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Female; Hep G2 Cells; Humans; Interferon Regulatory Factor-1; Liver Neoplasms; Mice; MicroRNAs; Neoplasm Transplantation; Phosphorylation; Prognosis; Pyrazines; Pyrazoles; STAT3 Transcription Factor; Up-Regulation

2021
CC-223 blocks mTORC1/C2 activation and inhibits human hepatocellular carcinoma cells in vitro and in vivo.
    PloS one, 2017, Volume: 12, Issue:3

    Topics: Aged; Animals; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; Hep G2 Cells; Humans; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, SCID; Middle Aged; Mitochondria; Multiprotein Complexes; Protein Kinase Inhibitors; Pyrazines; Reactive Oxygen Species; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2017
β1 integrin-mediated multicellular resistance in hepatocellular carcinoma through activation of the FAK/Akt pathway.
    The Journal of international medical research, 2018, Volume: 46, Issue:4

    Topics: Apoptosis; Benzamides; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Focal Adhesion Protein-Tyrosine Kinases; Humans; Integrin beta1; Liver Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; Spheroids, Cellular; Sulfonamides

2018
Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
    Cellular oncology (Dordrecht), 2018, Volume: 41, Issue:3

    Topics: Actin Cytoskeleton; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Insulin-Like Growth Factor I; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Pyrroles; Sorafenib; Vitamin K 1

2018
Determination of uric acid in serum using an optical sensor based on binuclear Pd(II) 2-pyrazinecarboxamide-bipyridine doped in a sol gel matrix.
    Talanta, 2019, Jul-01, Volume: 199

    Topics: 2,2'-Dipyridyl; Carcinoma, Hepatocellular; Cardiovascular Diseases; Coordination Complexes; Gels; Humans; Liver Neoplasms; Optical Devices; Optical Imaging; Palladium; Pyrazines; Uric Acid

2019
Bortezomib congeners induce apoptosis of hepatocellular carcinoma via CIP2A inhibition.
    Molecules (Basel, Switzerland), 2013, Dec-11, Volume: 18, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Autoantigens; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Knockdown Techniques; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Membrane Proteins; Molecular Structure; Pyrazines; Structure-Activity Relationship

2013
Bortezomib effect on E2F and cyclin family members in human hepatocellular carcinoma cell lines.
    World journal of gastroenterology, 2014, Jan-21, Volume: 20, Issue:3

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Proliferation; Cyclins; E2F Transcription Factors; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Phenotype; Proteasome Inhibitors; Pyrazines; RNA Interference; RNA, Messenger; Transfection

2014
Development of P22 viral capsid nanocomposites as anti-cancer drug, bortezomib (BTZ), delivery nanoplatforms.
    Macromolecular bioscience, 2014, Volume: 14, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Capsid Proteins; Carcinoma, Hepatocellular; Catechols; Drug Delivery Systems; Humans; Liver Neoplasms; Nanocomposites; Pyrazines

2014
Reactive oxygen species-mediated activation of the Src-epidermal growth factor receptor-Akt signaling cascade prevents bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Molecular medicine reports, 2015, Volume: 11, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Liver Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Reactive Oxygen Species; Signal Transduction; src-Family Kinases

2015
CXC195 suppresses proliferation and inflammatory response in LPS-induced human hepatocellular carcinoma cells via regulating TLR4-MyD88-TAK1-mediated NF-κB and MAPK pathway.
    Biochemical and biophysical research communications, 2015, Jan-02, Volume: 456, Issue:1

    Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Inflammation; Lipopolysaccharides; Liver Neoplasms; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Myeloid Differentiation Factor 88; NF-kappa B; Piperazines; Pyrazines; Toll-Like Receptor 4

2015
A New Ligustrazine Derivative-Selective Cytotoxicity by Suppression of NF-κB/p65 and COX-2 Expression on Human Hepatoma Cells. Part 3.
    International journal of molecular sciences, 2015, Jul-17, Volume: 16, Issue:7

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cyclooxygenase 2; Dogs; HeLa Cells; HT29 Cells; Humans; Madin Darby Canine Kidney Cells; Pyrazines; Transcription Factor RelA

2015
CXC195 induces apoptosis and endoplastic reticulum stress in human hepatocellular carcinoma cells by inhibiting the PI3K/Akt/mTOR signaling pathway.
    Molecular medicine reports, 2015, Volume: 12, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Endoplasmic Reticulum Stress; Hep G2 Cells; Humans; Phosphatidylinositol 3-Kinases; Piperazines; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; TOR Serine-Threonine Kinases

2015
The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.
    Oncotarget, 2016, Mar-01, Volume: 7, Issue:9

    Topics: alpha-Fetoproteins; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Combinations; Everolimus; Extracellular Signal-Regulated MAP Kinases; G1 Phase Cell Cycle Checkpoints; Hep G2 Cells; Humans; Imidazoles; Insulin; Liver Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazines; Receptor, IGF Type 1; Receptors, Somatomedin; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Messenger; Sirolimus; TOR Serine-Threonine Kinases

2016
Antihepatocellular Carcinoma Potential of Tetramethylpyrazine Induces Cell Cycle Modulation and Mitochondrial-Dependent Apoptosis: Regulation of p53 Signaling Pathway in HepG2 Cells In Vitro.
    Integrative cancer therapies, 2016, Volume: 15, Issue:2

    Topics: Apoptosis; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cytochromes c; G1 Phase Cell Cycle Checkpoints; Hep G2 Cells; Humans; Liver Neoplasms; Membrane Potential, Mitochondrial; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Resting Phase, Cell Cycle; Signal Transduction; Tumor Suppressor Protein p53

2016
Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jun-01, Volume: 14, Issue:11

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Fluorescent Antibody Technique; GPI-Linked Proteins; Histocompatibility Antigens Class I; Humans; Intercellular Signaling Peptides and Proteins; Interferon-gamma; Killer Cells, Natural; Liver Neoplasms; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction

2008
Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Cancer research, 2008, Aug-15, Volume: 68, Issue:16

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Cycle; Down-Regulation; Flow Cytometry; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; NF-kappa B; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2008
Inhibition of arachidonic acid and iron-induced mitochondrial dysfunction and apoptosis by oltipraz and novel 1,2-dithiole-3-thione congeners.
    Molecular pharmacology, 2009, Volume: 75, Issue:1

    Topics: Apoptosis; Arachidonic Acid; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Formazans; Humans; In Situ Nick-End Labeling; Iron; Liver Neoplasms; Membrane Potential, Mitochondrial; Mitochondria; Pyrazines; Reactive Oxygen Species; Tetrazolium Salts; Thiones; Thiophenes; Time Factors

2009
Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels.
    Biochimie, 2009, Volume: 91, Issue:3

    Topics: Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Dose-Response Relationship, Drug; E2F1 Transcription Factor; G2 Phase; Humans; Liver Neoplasms; Pyrazines; RNA, Messenger; S Phase; Time Factors

2009
Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway.
    The Journal of biological chemistry, 2009, Apr-24, Volume: 284, Issue:17

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Chromones; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Liver Neoplasms; Morpholines; NF-kappa B; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand

2009
Involvement of pregnane X receptor in the regulation of CYP2B6 gene expression by oltipraz in human hepatocytes.
    Toxicology in vitro : an international journal published in association with BIBRA, 2010, Volume: 24, Issue:2

    Topics: Anticarcinogenic Agents; Aryl Hydrocarbon Hydroxylases; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytochrome P-450 CYP2B6; Gene Expression Regulation; Hepatocytes; Humans; Hydroxylation; Liver Neoplasms; Oxidoreductases, N-Demethylating; Pregnane X Receptor; Pyrazines; Receptors, Steroid; RNA, Messenger; Testosterone; Thiones; Thiophenes

2010
Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
    Journal of hepatology, 2010, Volume: 52, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Niacinamide; Okadaic Acid; Phenylurea Compounds; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Pyrazines; Pyridines; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays

2010
Inhibition of tetramethylpyrazine on P-gp, MRP2, MRP3 and MRP5 in multidrug resistant human hepatocellular carcinoma cells.
    Oncology reports, 2010, Volume: 23, Issue:1

    Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Hepatocellular; Cell Line, Tumor; Doxorubicin; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Liver Neoplasms; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Plant Extracts; Plant Roots; Pyrazines

2010
G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation.
    Carcinogenesis, 2010, Volume: 31, Issue:7

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line; GTP-Binding Protein alpha Subunits, G12-G13; Humans; In Situ Nick-End Labeling; Liver Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RNA, Messenger

2010
Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma.
    Gut, 2010, Volume: 59, Issue:10

    Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Combined Modality Therapy; Endoplasmic Reticulum; Female; Immunity, Cellular; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Oncolytic Virotherapy; Proteasome Inhibitors; Pyrazines; Stress, Physiological; Tumor Cells, Cultured; Unfolded Protein Response; Xenograft Model Antitumor Assays

2010
CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells.
    Oncogene, 2010, Nov-25, Volume: 29, Issue:47

    Topics: Animals; Apoptosis; Autoantigens; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Mice; Mice, Nude; Phosphoproteins; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Pyrazines; RNA, Small Interfering; Transcription, Genetic; Up-Regulation; Xenograft Model Antitumor Assays

2010
Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A.
    Molecular cancer therapeutics, 2011, Volume: 10, Issue:5

    Topics: Animals; Antibodies, Neoplasm; Apoptosis; Autoantigens; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Male; Membrane Proteins; Mice; Mice, Nude; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays

2011
Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines.
    Anticancer research, 2011, Volume: 31, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunoblotting; Liver Neoplasms; Magnetic Resonance Spectroscopy; Metabolomics; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Sulfonamides

2011
Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:2

    Topics: Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Imidazoles; Insulin-Like Growth Factor II; Liver Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Receptor, IGF Type 1; Receptor, Insulin; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction

2012
Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma.
    Cancer, 2012, Nov-15, Volume: 118, Issue:22

    Topics: Adenine; Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chloroquine; Cysteine Proteinase Inhibitors; Humans; Leupeptins; Membrane Proteins; Microtubule-Associated Proteins; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2012
Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
    BMC cancer, 2012, May-04, Volume: 12

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Proto-Oncogene Proteins c-akt; Pyrazines; Sirolimus; TOR Serine-Threonine Kinases; Tumor Burden; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2012
Combination treatment with bortezomib and thiostrepton is effective against tumor formation in mouse models of DEN/PB-induced liver carcinogenesis.
    Cell cycle (Georgetown, Tex.), 2012, Sep-15, Volume: 11, Issue:18

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Diethylnitrosamine; Disease Models, Animal; Liver; Liver Neoplasms; Mice; Phenobarbital; Pyrazines; Thiostrepton

2012
Upregulation of focal adhesion kinase by 14-3-3ε via NFκB activation in hepatocellular carcinoma.
    Anti-cancer agents in medicinal chemistry, 2013, Volume: 13, Issue:4

    Topics: 14-3-3 Proteins; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Survival; Drug Screening Assays, Antitumor; Female; Focal Adhesion Protein-Tyrosine Kinases; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; NF-kappa B; Pyrazines; Structure-Activity Relationship; Tumor Cells, Cultured; Up-Regulation

2013
Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib.
    Hepatology (Baltimore, Md.), 2013, Volume: 57, Issue:2

    Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; ErbB Receptors; Hepatocytes; Humans; Liver Neoplasms; Molecular Targeted Therapy; Pyrazines; Recombinant Fusion Proteins; TNF-Related Apoptosis-Inducing Ligand

2013
Bortezomib induces tumor-specific cell death and growth inhibition in hepatocellular carcinoma and improves liver fibrosis.
    Journal of gastroenterology, 2013, Volume: 48, Issue:6

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Death; Liver Cirrhosis; Liver Neoplasms; Male; Pyrazines; Rats; Rats, Wistar

2013
Possible involvement of glutathione balance disruption in dihydropyrazine-induced cytotoxicity on human hepatoma HepG2 cells.
    The Journal of toxicological sciences, 2012, Volume: 37, Issue:5

    Topics: Carcinoma, Hepatocellular; Cell Survival; Glutathione; Glutathione Disulfide; Hep G2 Cells; Humans; Liver Neoplasms; Pyrazines

2012
Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome.
    PloS one, 2013, Volume: 8, Issue:2

    Topics: Acridine Orange; Autoantigens; Autophagy; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Membrane Proteins; Microscopy, Fluorescence; Phosphorylation; Proteasome Endopeptidase Complex; Protein Phosphatase 2; Pyrazines; Time Factors

2013
[Study on ligustrazine in reversing multidrug resistance of HepG2/ADM cell in vitro].
    Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2004, Volume: 29, Issue:10

    Topics: ATP Binding Cassette Transporter, Subfamily B; Calcium Channel Blockers; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytotoxicity, Immunologic; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Genes, MDR; Glycoproteins; Humans; Liver Neoplasms; Pyrazines

2004
Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.
    Hepatology (Baltimore, Md.), 2005, Volume: 42, Issue:3

    Topics: Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Culture Techniques; Cell Line, Tumor; Hepatocytes; Humans; Liver Neoplasms; Membrane Glycoproteins; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; RNA Interference; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha

2005
SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib.
    Apoptosis : an international journal on programmed cell death, 2007, Volume: 12, Issue:7

    Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Caspase 8; Cell Line, Tumor; Fas Ligand Protein; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Membrane Potential, Mitochondrial; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Vorinostat

2007
Hsp72 controls bortezomib-induced HepG2 cell death via interaction with pro-apoptotic factors.
    Oncology reports, 2007, Volume: 18, Issue:2

    Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Apoptosis Inducing Factor; Apoptosis Regulatory Proteins; Apoptotic Protease-Activating Factor 1; bcl-2-Associated X Protein; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; HSP72 Heat-Shock Proteins; Humans; Immunoprecipitation; Liver Neoplasms; Protease Inhibitors; Protein Binding; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Tumor Suppressor Protein p53

2007
Impaired ability of neutrophils to produce oxygen-derived free radicals in patients with chronic liver disease and hepatocellular carcinoma.
    Hepatology (Baltimore, Md.), 1994, Volume: 20, Issue:2

    Topics: Alanine Transaminase; Bilirubin; Carcinoma, Hepatocellular; Chronic Disease; Female; Free Radicals; Hepatitis, Chronic; Humans; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Luminescent Measurements; Luminol; Male; Middle Aged; Neutrophils; Oxygen; Prothrombin Time; Pyrazines; Serum Albumin

1994
Antitumor effect of vesnarinone on human hepatocellular carcinoma cell lines.
    International journal of oncology, 1999, Volume: 14, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Division; Dose-Response Relationship, Drug; Humans; In Situ Nick-End Labeling; Isoxazoles; Liver Neoplasms; Pyrazines; Quinolines; Tumor Cells, Cultured

1999
Hepatocarcinogenicity of the herbicide maleic hydrazide following parenteral administration to infant Swiss mice.
    International journal of cancer, 1968, May-15, Volume: 3, Issue:3

    Topics: Animals; Animals, Newborn; Carcinoma, Hepatocellular; Herbicides; Injections, Subcutaneous; Liver Neoplasms; Maleates; Mice; Pyrazines

1968